The "Omega 3 Prescription Drugs Market Size, Share & Trends Analysis Report By Drug, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030" report has been added to ResearchAndMarkets.com's offering.
The global omega 3 prescription drugs market size is expected to reach USD 1.80 billion in 2030 and is expected to expand at a CAGR of 4.90% by 2030.
The growth of the industry is attributed to the rising cases of Cardiovascular Diseases (CVDs) and altered dietary practices. An elevated level of triglycerides in the blood is now known to be associated with an increased risk of cardiovascular disease. According to the European Society of Cardiology in 2021, 17.9 million people die from CVDs each year, making it the leading cause of death worldwide. Furthermore, due to the expanding product application potential in medicines, omega 3-based pharmaceutical product launches by industry participants are anticipated to boost its growth.
For instance, in 2020, the U.S. FDA authorized a new cardiovascular indication and label expansion for the omega-3 medication VASCEPA, manufactured by U.S.-based Amarin Corporation. An increase in triglycerides can cause artery narrowing, which raises the risk of heart attack and stroke. Pancreatitis, an inflammation of the pancreas, can result from extremely high levels as well. Triglyceride levels rise as a result of diabetes and obesity, which is a widespread issue. An average of 25% of American adults have high borderline blood alcohol concentrations. The omega-3 fatty acid medications are prescribed only for triglycerides levels above 500 mg/dl as approved by the U.S. FDA. The omega 3 prescription drugs demonstrated a significant market movement during the COVID-19 pandemic.
This is owing to their significant role in the management of CVD patients. For instance, in August 2021, Woodward Pharma Services LLC announced the acquisition of LOVAZA from GlaxoSmithKline. The company further aims to educate consumers and providers to facilitate higher adoption of the product. Moreover, multiple R&D studies are being conducted for lowering triglycerides; combined and analyzed findings from 17 organized and randomized clinical trials on elevated triglyceride levels, suggest that prescription omega-3 fatty acid medication can reduce levels by 20-30%. This is expected to create high product demand.
Omega 3 Prescription Drugs Market Report Highlights
- Lovaza is projected to experience moderate growth opportunities during the forecast period.
- Cardiovascular dominated the market and accounted for the largest revenue share of 86.8% in 2024
- Retail pharmacy dominated the market and accounted for the largest revenue share of 53.6% in 2024 due to its wide accessibility and consumer convenience
- The online pharmacy segment is expected to witness moderate growth due to the increasing consumer preference for convenient and accessible healthcare solutions
- North America dominated the global omega 3 prescription drugs market with a share of 42.9% in 2024 and is anticipated to grow significantly over the forecast period.
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 80 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value (USD) in 2024 | $1.35 billion |
| Forecasted Market Value (USD) by 2030 | $1.8 billion |
| Compound Annual Growth Rate | 4.9% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Regional outlook
2.4. Competitive Insights
Chapter 3. Omega 3 Prescription Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising Prevalence of Cardiovascular Diseases
3.2.1.2. Growing Awareness of Omega-3 Health Benefits
3.2.1.3. Advancements in Pharmaceutical Formulations
3.2.2. Market Restraint Analysis
3.2.2.1. High Cost of Prescription Omega-3 Drugs
3.2.2.2. Regulatory and Reimbursement Challenges
3.3. Omega 3 Prescription Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter's
3.3.2. PESTEL Analysis
Chapter 4. Omega 3 Prescription Drugs Market: Drug Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Omega 3 Prescription Drugs Market: Drug Movement Analysis
4.3. Omega 3 Prescription Drugs Market by Drug (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Vascepa
4.6. Lovaza
4.7. Others
Chapter 5. Omega 3 Prescription Drugs Market: Application Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Omega 3 Prescription Drugs Market: Application Movement Analysis
5.3. Omega 3 Prescription Drugs Market by Application Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Cardiovascular
5.6. Others
Chapter 6. Omega 3 Prescription Drugs Market: Distribution Channel Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Omega 3 Prescription Drugs Market: Distribution Channel Movement Analysis
6.3. Omega 3 Prescription Drugs Market by Distribution Channel Outlook (USD Million)
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Hospital Pharmacy
6.6. Retail Pharmacy
6.7. Online Pharmacy
Chapter 7. Omega 3 Prescription Drugs Market: Regional Estimates & Trend Analysis
7.1. Regional Dashboard
7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.3. North America
7.4. Europe
7.5. Asia Pacific
7.6. Latin America
7.7. MEA
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Recent Developments & Impact Analysis by Key Market Participants
8.3. Company Market Share Analysis, 2024
8.4. Key Company Profiles
- Amarin Pharmaceuticals Ireland
- Woodward Pharma Services
- Mankind Pharma
- GLW Pharma
- CSPC Pharmaceutical Group
- Sofgen
- Wilshire Pharmaceuticals
- Sun Pharmaceutical Industries
- PuraCap Pharmaceutical
- ChartwellPharma
- Amneal Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/589dwj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116093452/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
